中智藥業(03737.HK)全年歸母淨利增長20.8%至1.39億元
格隆匯 3 月 25日丨中智藥業(03737.HK)公佈截至2020年12月31日止年度的全年業績,報吿期間內,集團繼續主要從事製藥及在中山市營運連鎖藥店。集團的收益上升約19.5%至約人民幣16.039億元。母公司擁有人應占利潤增長約20.8%至人民幣1.385億元,此歸因於新型飲片草晶華破壁草本的強勁增長,嚴格控制銷售及管理成本,以及對銷售模式進行細微調整所致。基本每股盈利人民幣0.17元,董事會擬定2020年年末暫不派息。2020年財政年度合計每股股息5.15港仙,包括中期股息每股3.70港仙及特別股息每股1.45港仙。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.